The main objective of the Investment approach is to generate capital appreciation through investments in equities with a medium to long-term perspective.
| Alpha (1Y) | Beta (1Y) | Standard Deviation (1Y) | % of +ve Months (SI) |
|---|---|---|---|
| 13.48% | 0.55 | 17.86% | 59.62% |
Performance Table #
| Trailing Returns (%) | 1m return | 3m return | 6m return | 1y return | 2y return | 3y return | 5y return | 10y return | Since inception return |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | 0.74% | -0.68% | -5.81% | 10.11% | 27.45% | 14.69% | 19.22% | - | 13.19% |
| NIFTY 50 TRI | 3.48% | 3.65% | 0.84% | 9.01% | 17.41% | 13.80% | 21.16% | - | 13.85% |
QRC Report Card *
| Strategy | Category | Fund Manager | Date of Inception | Age Of PMS | Corpus (in Cr, approx) | Benchmark | Returns SI (CAGR) | Stocks In Portfolio | Sectors In Portfolio |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | Multi Cap | Anshul Saigal | 20 September 2016 | 8Y 9M | 25 | NIFTY 50 TRI | 13.19% | 7 | 19 |
| Portfolio Quality (Q) | Portfolio Risk (R) | Portfolio Consistency (C) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Index | Category Alpha (1Y) | Relative Alpha (1Y) |
% of +ve Months
(Fund Data) |
Alpha (1Y) | Beta (1Y) |
Standard Deviation (1Y)
(Fund Data) |
Sharpe Ratio (1Y)
(Fund Data) |
Alpha (SI) | Information Ratio (SI) | Consistency Ratio % |
| Nifty 50 | 9.87% | -7.35% | 59.62% | 2.52% | 0.92 | 17.86% | 0.37 | 0.53% | 0.03 | 50.00 % |
| Nifty 500 | 10.47% | -5.22% | 5.25% | 0.87 | -0.16% | -0.01 | 49.04 % | |||
| Nifty Midcap 100 | 5.33% | -1.56% | 3.77% | 0.74 | -2.36% | -0.13 | 47.12 % | |||
| Nifty Smallcap 100 | 11.11% | 2.37% | 13.48% | 0.55 | 1.23% | 0.06 | 47.12 % | |||
VIEW DETAILED QUALITY, RISK, CONSISTENCY ANALYSIS
Portfolio Holdings
| Holding | % |
|---|---|
| ASTER DM HEALTHCARE LTD | 22.85 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 18.58 |
| CIPLA LTD | 18.16 |
| PIRAMAL PHARMA LTD | 14.23 |
| FORTIS HEALTHCARE LTD | 10.82 |
| METROPOLIS HEALTHCARE LTD | 7.50 |
| GLENMARK PHARMACEUTICALS LTD | 5.62 |
Sector Allocation
| Holding | % |
|---|---|
| PHARMA & BIOTECH | 5.62 |
| PHARMA & BIOTECH | 1.17 |
| PHARMA & BIOTECH | 16.46 |
| PHARMA & BIOTECH | 12.45 |
| HEALTHCARE SERVICES | 7.63 |
| PHARMA & BIOTECH | 2.99 |
| PHARMA & BIOTECH | 6.08 |
| HEALTHCARE SERVICES | 3.20 |
| PHARMA & BIOTECH | 5.71 |
| PHARMA & BIOTECH | 3.56 |
| HEALTHCARE SERVICES | 5.37 |
| PHARMA & BIOTECH | 3.80 |
| PHARMA & BIOTECH | 3.18 |
| PHARMA & BIOTECH | 6.08 |
| PHARMA & BIOTECH | 4.27 |
| PHARMA & BIOTECH | 1.69 |
| PHARMA & BIOTECH | 3.01 |
| PHARMA & BIOTECH | 3.93 |
| PHARMA & BIOTECH | 2.72 |
Market Cap Allocation
| Allocations | % |
|---|---|
| Large Cap | 36.70 |
| Mid Cap | 16.40 |
| Small Cap | 44.60 |
| Cash | 8.71 |
Do Not Simply Invest, Make Informed Decisions
WISH TO MAKE INFORMED INVESTMENTS FOR LONG TERM WEALTH CREATION
Book
a call with our PMS AIF Specialists
Disclaimer
#Returns as of 31 May 2025. Returns up to 1 Year are absolute, above 1 Year are CAGR.
*QRC Report Card data is updated quarterly. Current data is as of Apr 25.
